We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Actinium Pharmaceuticals (ATNM - Free Report) closed the most recent trading day at $11.16, moving -1.06% from the previous trading session. This change lagged the S&P 500's daily loss of 0.68%. Elsewhere, the Dow lost 0.75%, while the tech-heavy Nasdaq lost 0.42%.
Heading into today, shares of the cancer drug developer had lost 4.57% over the past month, lagging the Medical sector's gain of 2.1% and the S&P 500's gain of 4.61% in that time.
Investors will be hoping for strength from ATNM as it approaches its next earnings release. The company is expected to report EPS of -$0.46, up 61.67% from the prior-year quarter.
Investors might also notice recent changes to analyst estimates for ATNM. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 8.45% higher. ATNM is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 187, which puts it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ATNM in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know
Actinium Pharmaceuticals (ATNM - Free Report) closed the most recent trading day at $11.16, moving -1.06% from the previous trading session. This change lagged the S&P 500's daily loss of 0.68%. Elsewhere, the Dow lost 0.75%, while the tech-heavy Nasdaq lost 0.42%.
Heading into today, shares of the cancer drug developer had lost 4.57% over the past month, lagging the Medical sector's gain of 2.1% and the S&P 500's gain of 4.61% in that time.
Investors will be hoping for strength from ATNM as it approaches its next earnings release. The company is expected to report EPS of -$0.46, up 61.67% from the prior-year quarter.
Investors might also notice recent changes to analyst estimates for ATNM. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 8.45% higher. ATNM is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 187, which puts it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ATNM in the coming trading sessions, be sure to utilize Zacks.com.